Baird raises target for Intuitive Surgical stock from USD 513 to USD 550

Published on 10/22/2026 at 11:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

A USD 450 million charge cut GAAP profit in Q3 to USD 1.49 per share. Intuitive Surgical stock costs EUR 376.98 on October 22, 2026.

Earnings and valuation details

Intuitive Surgical reached a USD 450 million antitrust settlement on October 20, 2026.
Management guided for 14% to 15% da Vinci procedure growth in fiscal year 2026.
Intuitive Surgical stock trades at EUR 376.98 at 11:02 a.m. CEST at Lang & Schwarz on October 22, 2026.
Market capitalization stood at USD 151.2 billion as of October 21, 2026.

Pop-Art-Comicillustration mit Halbton-Punktmuster in Cyan, Magenta, Gelb und Schwarz, zeigt Chirurgen an Konsole mit dramatisch ausgefahrenen Roboterarmen, 1960er-Retro-Comicbuch-Ästhetik — Intuitive Surgical US46120E6023 Pop Art Comic zeigt futuristisches Roboterchirurgie Szenario in kräftigen Halbtontönen, Illustration mit AI erstellt.

Intuitive Surgical (ISIN US46120E6023) saw Baird raise its price target from USD 513 to USD 550 on October 21, 2026, as reported by Benzinga. The revision followed third-quarter results that beat revenue and adjusted earnings expectations, while management narrowed its full-year procedure outlook.

Targets diverge after results

Baird kept an Outperform rating while lifting its target to USD 550 from USD 513. Mizuho cut its target to USD 400 from USD 415, RBC Capital lowered its target to USD 550 from USD 575, and Barclays raised its target to USD 500 from USD 485, according to Benzinga.

The third quarter produced USD 3.05 billion in revenue, up 22% from USD 2.51 billion in the third quarter of 2025. Non-GAAP earnings per share reached USD 3.00, compared with USD 2.40 a year earlier, while GAAP earnings per share fell to USD 1.49 from USD 1.95 after a USD 450 million antitrust settlement charge, according to Morningstar.

What does the outlook mean?

Management narrowed its fiscal year 2026 da Vinci procedure growth outlook to 14% to 15%, compared with the earlier range of 13.5% to 15.5%. It also set a non-GAAP gross profit margin range of 68.7% to 69.3%, including an estimated 0.9% tariff impact, according to Morningstar.

Three dated milestones

On September 8, 2026, Intuitive highlighted a meta-analysis covering 13 benign conditions through its investor-relations materials at Intuitive Surgical. On October 20, 2026, the company reported third-quarter revenue of USD 3.05 billion and placed 546 da Vinci systems, versus 427 a year earlier, according to Morningstar. On October 21, 2026, Baird, Mizuho, RBC Capital, and Barclays revised their targets, according to Benzinga.

Reporting dates and market value

The October 20, 2026 earnings release covered the quarter ended September 30, 2026, while the October 21, 2026 analyst notes followed the release. The company had 12,094 da Vinci systems installed at September 30, 2026, up 12% from 10,763 a year earlier.

Stock trades below its US reference

Intuitive Surgical stock was trading at EUR 376.98 at Lang & Schwarz on October 22, 2026 at 11:02 a.m. CEST. The primary Nasdaq quote was last at USD 428.12 on October 21, 2026 at 4:00 p.m. ET, while the market capitalization was USD 151.2 billion and the 52-week range was USD 328.57 to USD 603.88.

The further course of trading is shown by the continuously updated real-time quote of Intuitive Surgical stock.